{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T09:53:33Z","timestamp":1791971613735,"version":"4.3.4"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"vor","delay-in-days":162,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Intensive Care"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.aicoj.2026.100100","type":"journal-article","created":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T17:46:29Z","timestamp":1781459189000},"page":"100100","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Improved survival in patients admitted to ICU with multiple myeloma: a retrospective cohort analysis"],"prefix":"10.1016","volume":"16","author":[{"given":"Sabrine","family":"Nakaa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo","family":"Caillot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akli","family":"Chermak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helene","family":"Kemp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Harel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Darmon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elie","family":"Azoulay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginie","family":"Lemiale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.aicoj.2026.100100_bib0005","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1056\/NEJMoa2400712","article-title":"Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"391","author":"Facon","year":"2024","journal-title":"N Engl J Med."},{"key":"10.1016\/j.aicoj.2026.100100_bib0010","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med."},{"key":"10.1016\/j.aicoj.2026.100100_bib0015","article-title":"Effectiveness and safety of teclistamab for relapsed or refractory multiple myeloma: a systematic review and meta-analysis","volume":"16","author":"Li","year":"2025","journal-title":"Front Immunol."},{"key":"10.1016\/j.aicoj.2026.100100_bib0020","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med."},{"key":"10.1016\/j.aicoj.2026.100100_bib0025","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1038\/s41591-024-03050-2","article-title":"Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial","volume":"30","author":"Leleu","year":"2024","journal-title":"Nat Med."},{"key":"10.1016\/j.aicoj.2026.100100_bib0030","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1056\/NEJMoa2505133","article-title":"Measurable residual disease-guided therapy in newly diagnosed myeloma","volume":"393","author":"Perrot","year":"2025","journal-title":"N Engl J Med."},{"key":"10.1016\/j.aicoj.2026.100100_bib0035","article-title":"Carfilzomib in multiple myeloma: unraveling cardiac toxicities - from mechanisms to diagnosis and management","volume":"16","author":"Gao","year":"2025","journal-title":"Front Pharmacol."},{"key":"10.1016\/j.aicoj.2026.100100_bib0040","doi-asserted-by":"crossref","first-page":"7572","DOI":"10.3390\/jcm13247572","article-title":"Emergencies in hematology: why, when and how i treat?","volume":"13","author":"Duminuco","year":"2024","journal-title":"J Clin Med."},{"key":"10.1016\/j.aicoj.2026.100100_bib0045","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1158\/2643-3230.BCD-20-0102","article-title":"COVID-19 infections and clinical outcomes in patients with multiple myeloma in New York city: a cohort study from five academic centers","volume":"1","author":"Hultcrantz","year":"2020","journal-title":"Blood Cancer Discov."},{"key":"10.1016\/j.aicoj.2026.100100_bib0050","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"390","author":"Sonneveld","year":"2024","journal-title":"N Engl J Med."},{"key":"10.1016\/j.aicoj.2026.100100_bib0055","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1007\/s00134-008-1320-4","article-title":"Continued survival gains in recent years among critically ill myeloma patients","volume":"35","author":"Peigne","year":"2009","journal-title":"Intensive Care Med [Internet]."},{"key":"10.1016\/j.aicoj.2026.100100_bib0060","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.blre.2015.04.002","article-title":"Managing critically Ill hematology patients: time to think differently","volume":"29","author":"Azoulay","year":"2015","journal-title":"Blood Rev."},{"key":"10.1016\/j.aicoj.2026.100100_bib0065","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.1200\/JCO.2012.47.2365","article-title":"Outcomes of critically ill patients with hematologic malignancies: prospective multicenter data from France and Belgium--a groupe de recherche respiratoire en r\u00e9animation onco-h\u00e9matologique study","volume":"31","author":"Azoulay","year":"2013","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.aicoj.2026.100100_bib0070","doi-asserted-by":"crossref","DOI":"10.1038\/s41571-025-01041-x","article-title":"EHA-EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma","author":"Dimopoulos","year":"2025","journal-title":"Nat Rev Clin Oncol."},{"key":"10.1016\/j.aicoj.2026.100100_bib0075","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U","article-title":"A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival","volume":"36","author":"Durie","year":"1975","journal-title":"Cancer."},{"key":"10.1016\/j.aicoj.2026.100100_bib0080","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S2352-3026(21)00283-0","article-title":"Consensus guidelines and recommendations for infection prevention in multiple Myeloma: a report from the International Myeloma Working Group","volume":"9","author":"Raje","year":"2022","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.aicoj.2026.100100_bib0085","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1080\/16078454.2020.1845502","article-title":"Prognostic factors for patients with multiple myeloma admitted to the intensive care unit","volume":"25","author":"Diao","year":"2020","journal-title":"Hematology."},{"key":"10.1016\/j.aicoj.2026.100100_bib0090","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1097\/01.CCM.0000181728.13354.0A","article-title":"Intensive care in patients with newly diagnosed malignancies and a need for cancer chemotherapy","volume":"33","author":"Darmon","year":"2005","journal-title":"Crit Care Med."},{"key":"10.1016\/j.aicoj.2026.100100_bib0095","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1097\/01.CCM.0000256846.27192.7A","article-title":"The ICU Trial: a new admission policy for cancer patients requiring mechanical ventilation","volume":"35","author":"Lecuyer","year":"2007","journal-title":"Crit Care Med [Internet]"},{"key":"10.1016\/j.aicoj.2026.100100_bib0100","doi-asserted-by":"crossref","first-page":"13099","DOI":"10.1182\/blood-2022-165911","article-title":"Outcome in multiple myeloma patients treated in the era of modern therapies who were admitted to intensive care: a retrospective analysis from a teaching hospital between 2014 and 2019","volume":"140","author":"Gross","year":"2022","journal-title":"Blood [Internet]"},{"key":"10.1016\/j.aicoj.2026.100100_bib0105","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1001\/jamainternmed.2021.1000","article-title":"Evaluation of time-limited trials among critically ill patients with advanced medical illnesses and reduction of nonbeneficial ICU treatments","volume":"181","author":"Chang","year":"2021","journal-title":"JAMA Intern Med."},{"key":"10.1016\/j.aicoj.2026.100100_bib0110","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1007\/s00277-025-06303-3","article-title":"Health-related quality of life with daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible patients with newly diagnosed multiple myeloma: analysis of the phase 3 OCTANS study","volume":"104","author":"Fu","year":"2025","journal-title":"Ann Hematol."},{"key":"10.1016\/j.aicoj.2026.100100_bib0115","doi-asserted-by":"crossref","first-page":"5849","DOI":"10.1007\/s00277-024-06129-5","article-title":"Patient-reported outcome domains in multiple myeloma randomized controlled trials and association with survival outcomes","volume":"103","author":"Shah","year":"2024","journal-title":"Ann Hematol."},{"key":"10.1016\/j.aicoj.2026.100100_bib0120","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jcrc.2020.10.008","article-title":"Impact of early ICU admission on outcome of critically ill and critically ill cancer patients: a systematic review and meta-analysis","volume":"61","author":"Hourmant","year":"2021","journal-title":"J Crit Care."},{"key":"10.1016\/j.aicoj.2026.100100_bib0125","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.3109\/10428194.2012.753446","article-title":"Delayed intensive care unit admission is associated with increased mortality in patients with cancer with acute respiratory failure","volume":"54","author":"Mokart","year":"2013","journal-title":"Leuk Lymphoma."}],"container-title":["Annals of Intensive Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2110582026001354?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2110582026001354?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T09:29:32Z","timestamp":1791970172000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2110582026001354"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":25,"alternative-id":["S2110582026001354"],"URL":"https:\/\/doi.org\/10.1016\/j.aicoj.2026.100100","relation":{},"ISSN":["2110-5820"],"issn-type":[{"value":"2110-5820","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Improved survival in patients admitted to ICU with multiple myeloma: a retrospective cohort analysis","name":"articletitle","label":"Article Title"},{"value":"Annals of Intensive Care","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.aicoj.2026.100100","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 de R\u00e9animation de Langue Fran\u00e7aise (French Intensive Care Society).","name":"copyright","label":"Copyright"}],"article-number":"100100"}}